- Home
- NXTC vs ELBM Comparison
NXTC vs ELBM Comparison
Compare NXTC & ELBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ELBM
- Stock Information
- Founded
- NXTC 2015
- ELBM 2011
- Country
- NXTC United States
- ELBM Canada
- Employees
- NXTC N/A
- ELBM N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ELBM Industrial Machinery/Components
- Sector
- NXTC Health Care
- ELBM Miscellaneous
- Exchange
- NXTC Nasdaq
- ELBM Nasdaq
- Market Cap
- NXTC 21.6M
- ELBM 25.0M
- IPO Year
- NXTC 2019
- ELBM N/A
- Fundamental
- Price
- NXTC $0.72
- ELBM $1.54
- Analyst Decision
- NXTC Strong Buy
- ELBM Strong Buy
- Analyst Count
- NXTC 2
- ELBM 1
- Target Price
- NXTC $4.00
- ELBM $5.20
- AVG Volume (30 Days)
- NXTC 61.8K
- ELBM 24.1K
- Earning Date
- NXTC 03-20-2025
- ELBM 11-15-2024
- Dividend Yield
- NXTC N/A
- ELBM N/A
- EPS Growth
- NXTC N/A
- ELBM N/A
- EPS
- NXTC N/A
- ELBM N/A
- Revenue
- NXTC N/A
- ELBM N/A
- Revenue This Year
- NXTC N/A
- ELBM N/A
- Revenue Next Year
- NXTC N/A
- ELBM $1,630.56
- P/E Ratio
- NXTC N/A
- ELBM N/A
- Revenue Growth
- NXTC N/A
- ELBM N/A
- 52 Week Low
- NXTC $0.66
- ELBM $1.04
- 52 Week High
- NXTC $2.57
- ELBM $2.83
- Technical
- Relative Strength Index (RSI)
- NXTC 40.34
- ELBM 44.45
- Support Level
- NXTC $0.66
- ELBM $1.51
- Resistance Level
- NXTC $0.79
- ELBM $1.61
- Average True Range (ATR)
- NXTC 0.06
- ELBM 0.12
- MACD
- NXTC 0.00
- ELBM -0.00
- Stochastic Oscillator
- NXTC 42.21
- ELBM 38.64
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.